NCT00596804 2021-08-18Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's LymphomaGilead SciencesPhase 1/2 Completed39 enrolled
NCT00989586 2017-02-06Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin LymphomaOhio State University Comprehensive Cancer CenterPhase 1/2 Completed35 enrolled 11 charts